A research team reported an open, publicly available tumor organoid biobank that maps gene dependencies across 256 clinically annotated organoids, alongside multi-omics profiling and genome-wide CRISPR–Cas9 screens. The study derived organoids directly from colorectal, oesophageal, ovarian, pancreatic, and gastric cancers and paired them with whole-genome and transcriptome sequencing from matched patient tumors. Across 162 organoids, the authors ran CRISPR–Cas9 screens to identify essential genes and targetable vulnerabilities. In colorectal cancer, functional and pharmacological experiments targeting the EGFR–RAS–MAPK axis exposed differential effects tied to KRAS variant alleles, highlighting how patient-relevant genetics can shape therapeutic response. By combining clinical annotation with dependency mapping and paired pre- and post-treatment samples, the biobank aims to reduce reliance on adapted cell lines that may not capture patient-linked biology.